Skip to content

Study · Animal study (in vivo) · rat · 1993

6 results

Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis.

Häyry P, Räisänen A, Ustinov J, Mennander A, Paavonen T

FASEB journal : official publication of the Federation of American Societies for Experimental Biology1 Aug 1993Cited by 42 (Europe PMC)

PMID8370476 (opens in a new tab)DOI10.1096/fasebj.7.11.8370476 (opens in a new tab)PepBankPUB-08370476
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rat aortic allografts undergoing chronic rejection, lanreotide strongly inhibited myocyte proliferation in vivo.

    In plain wordsIn rats with aortic allografts undergoing chronic rejection, lanreotide inhibited myocyte proliferation.

    Peptide
    Lanreotide
    Outcome
    DecreaseMyocyte proliferation
    Study

    ratn: not reported in source

    Aortic allografts undergoing chronic rejection
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Administration of a stable somatostatin analog lanreotide, BIM 23014, strongly inhibits myocyte proliferation in the allograft in vivo.
    1 context sentence
    Summary · context
    In this study we demonstrate that nonimmunosuppressed rat aortic allografts undergoing chronic rejection synthesize increased quantities of several smooth muscle cell growth-promoting substances in the vascular wall including interleukin-1, eicosanoids, and several peptide growth factors.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rat aortic allografts, lanreotide significantly reduced locally produced epidermal growth factor.

    In plain wordsIn rats with aortic allografts, lanreotide reduced locally produced epidermal growth factor.

    Peptide
    Lanreotide
    Outcome
    DecreaseEpidermal growth factor
    Study

    ratn: not reported in source

    Aortic allografts undergoing chronic rejection
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Concomitantly, the locally produced peptide growth factors, i.e., epidermal growth factor, insulin-like growth factor 1, and BB-isomer of platelet-derived growth factor, but not other mediators of inflammation, are significantly reduced.
    2 context sentences
    Summary · context
    Administration of a stable somatostatin analog lanreotide, BIM 23014, strongly inhibits myocyte proliferation in the allograft in vivo.
    Summary · context
    In this study we demonstrate that nonimmunosuppressed rat aortic allografts undergoing chronic rejection synthesize increased quantities of several smooth muscle cell growth-promoting substances in the vascular wall including interleukin-1, eicosanoids, and several peptide growth factors.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rat aortic allografts, lanreotide significantly reduced locally produced insulin-like growth factor 1.

    In plain wordsIn rats with aortic allografts, lanreotide reduced locally produced insulin-like growth factor 1.

    Peptide
    Lanreotide
    Outcome
    DecreaseInsulin-like growth factor 1
    Study

    ratn: not reported in source

    Aortic allografts undergoing chronic rejection
    Outcome group
    Growth hormone and IGF-1 · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Concomitantly, the locally produced peptide growth factors, i.e., epidermal growth factor, insulin-like growth factor 1, and BB-isomer of platelet-derived growth factor, but not other mediators of inflammation, are significantly reduced.
    2 context sentences
    Summary · context
    Administration of a stable somatostatin analog lanreotide, BIM 23014, strongly inhibits myocyte proliferation in the allograft in vivo.
    Summary · context
    In this study we demonstrate that nonimmunosuppressed rat aortic allografts undergoing chronic rejection synthesize increased quantities of several smooth muscle cell growth-promoting substances in the vascular wall including interleukin-1, eicosanoids, and several peptide growth factors.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rat aortic allografts, lanreotide significantly reduced locally produced BB-isomer of platelet-derived growth factor.

    In plain wordsIn rats with aortic allografts, lanreotide reduced locally produced BB-isomer of platelet-derived growth factor.

    Peptide
    Lanreotide
    Outcome
    DecreasePlatelet-derived growth factor BB
    Study

    ratn: not reported in source

    Aortic allografts undergoing chronic rejection
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Concomitantly, the locally produced peptide growth factors, i.e., epidermal growth factor, insulin-like growth factor 1, and BB-isomer of platelet-derived growth factor, but not other mediators of inflammation, are significantly reduced.
    2 context sentences
    Summary · context
    Administration of a stable somatostatin analog lanreotide, BIM 23014, strongly inhibits myocyte proliferation in the allograft in vivo.
    Summary · context
    In this study we demonstrate that nonimmunosuppressed rat aortic allografts undergoing chronic rejection synthesize increased quantities of several smooth muscle cell growth-promoting substances in the vascular wall including interleukin-1, eicosanoids, and several peptide growth factors.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rat aortic allografts, lanreotide did not significantly reduce other inflammatory mediators.

    In plain wordsIn rats with aortic allografts, lanreotide did not significantly reduce other inflammatory mediators.

    Peptide
    Lanreotide
    Outcome
    No significant changeOther inflammatory mediators
    Study

    ratn: not reported in source

    Aortic allografts undergoing chronic rejection
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Concomitantly, the locally produced peptide growth factors, i.e., epidermal growth factor, insulin-like growth factor 1, and BB-isomer of platelet-derived growth factor, but not other mediators of inflammation, are significantly reduced.
    2 context sentences
    Summary · context
    Administration of a stable somatostatin analog lanreotide, BIM 23014, strongly inhibits myocyte proliferation in the allograft in vivo.
    Summary · context
    In this study we demonstrate that nonimmunosuppressed rat aortic allografts undergoing chronic rejection synthesize increased quantities of several smooth muscle cell growth-promoting substances in the vascular wall including interleukin-1, eicosanoids, and several peptide growth factors.
  6. 06LabIn vitro (cells)Efficacy outcome

    In cultured smooth muscle cells, lanreotide did not inhibit proliferation.

    In plain wordsIn cells, lanreotide did not inhibit smooth muscle cell proliferation.

    Peptide
    Lanreotide
    Outcome
    No significant changeSmooth muscle cell proliferation
    Study

    n: not reported in source

    Smooth muscle cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It has no inhibitory effect on the proliferation of smooth muscle cells in vitro.
    1 context sentence
    Summary · context
    Administration of a stable somatostatin analog lanreotide, BIM 23014, strongly inhibits myocyte proliferation in the allograft in vivo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.